title: The evaluation of bone metabolism in children with renal transplantation.
abstract: This study aims to evaluate BMD and bone biomarkers and to investigate the effects of immunosuppressives on bone disease after RTx. Thirty-three RTR aged 16.7 ± 3.7 yr and healthy controls (n = 32) were enrolled. There was no difference between pre-RTx BMD and BMD at the time of study (45.9 ± 30.9 months after RTx), while both values were lower than controls (p < 0.01 and p < 0.05, respectively). Worst BMD scores were obtained at sixth month after RTx (-0.2 ± 0.9) and best at fourth year (1.4 ± 1.3). 25-hydroxy-(OH) vitamin D and OPG were higher in RTR (p < 0.001). BMD z scores negatively correlated with OPG and cumulative CS doses at the time of study (r = -0.344, p < 0.05 and r = -0.371, p < 0.05, respectively). Regression analysis revealed OPG as the only predictor of BMD (β -0.78, 95% CI -0.004 to -0.013, p < 0.001). The increase in OPG, a significant predictor of BMD, could either be secondary to graft dysfunction or for protection against bone loss. CS doses should be minimized to avoid their untoward effects on bone metabolism.
authors.affiliation: Division of Pediatric Nephrology, Gazi University, Ankara, Turkey.
authors.forename: Bahar
authors.initials: B
authors.lastname: Büyükkaragöz
authors.forename: Sevcan A
authors.initials: SA
authors.lastname: Bakkaloglu
authors.forename: Yaşar
authors.initials: Y
authors.lastname: Kandur
authors.forename: Emel
authors.initials: E
authors.lastname: Isiyel
authors.forename: Meltem
authors.initials: M
authors.lastname: Akcaboy
authors.forename: Necla
authors.initials: N
authors.lastname: Buyan
authors.forename: Enver
authors.initials: E
authors.lastname: Hasanoglu
mesh_terms: D000293:Adolescent; D000886:Anthropometry; D015415:Biomarkers / Q000378:metabolism; D015519:Bone Density; D001842:Bone and Bones / Q000378:metabolism* / Q000473:pathology; D016022:Case-Control Studies; D002648:Child; D002675:Child, Preschool; D005260:Female; D000089703:Fibroblast Growth Factor-23; D005346:Fibroblast Growth Factors / Q000378:metabolism; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016030:Kidney Transplantation; D008297:Male; D053244:Osteoprotegerin / Q000378:metabolism; D010281:Parathyroid Hormone / Q000378:metabolism; D053245:RANK Ligand / Q000378:metabolism; D051437:Renal Insufficiency / Q000097:blood / Q000473:pathology / Q000601:surgery*; D014807:Vitamin D / Q000031:analogs & derivatives / Q000378:metabolism; D055815:Young Adult
chemical_list: D015415:Biomarkers; D007166:Immunosuppressive Agents; D053244:Osteoprotegerin; C470125:PTH protein, human; D010281:Parathyroid Hormone; D053245:RANK Ligand; C505688:TNFSF11 protein, human; D014807:Vitamin D; D005346:Fibroblast Growth Factors; C097949:1,25-dihydroxyvitamin D; D000089703:Fibroblast Growth Factor-23; C104450:25-hydroxyvitamin D
keywords: bone metabolism; bone mineral density; children; corticosteroids; renal transplantation